NCT06393335View on ClinicalTrials.gov

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

March 15, 2026

Conditions
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
Interventions
DRUG

Metabolically Armed CD19 CAR-T cells

Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.

Trial Locations (1)

Unknown

RECRUITING

Children's Hospital of Zhejiang University School of Medicine, Hangzhou

Sponsors

Collaborators (1)

Leman Biotech Co., Ltd.
All Listed Sponsors
collaborator

Leman Biotech Co., Ltd.

INDUSTRY

lead

The Children's Hospital of Zhejiang University School of Medicine

OTHER